tegafur has been researched along with Bilirubinemia in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among these patients, 8 developed hyperbilirubinemia." | 5.33 | [Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer]. ( Fujii, K; Iizuka, R; Ikawa, O; Izumi, H; Kakihara, N; Katoh, Y; Matsumura, H; Miyata, K; Ohgaki, M; Shimomura, K; Shimotsuma, M; Tkenaka, A, 2006) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| " Pharmacokinetic parameters [ftorafur, uracil, 5-fluorouracil (5-FU), 5-methyltetrahydrofolate] showed wide interpatient variations." | 2.68 | A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. ( Creaven, PJ; Frank, C; Ho, DH; Kurowski, M; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1996) |
| "Among these patients, 8 developed hyperbilirubinemia." | 1.33 | [Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer]. ( Fujii, K; Iizuka, R; Ikawa, O; Izumi, H; Kakihara, N; Katoh, Y; Matsumura, H; Miyata, K; Ohgaki, M; Shimomura, K; Shimotsuma, M; Tkenaka, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kudo, M | 1 |
| Moriguchi, M | 1 |
| Numata, K | 1 |
| Hidaka, H | 1 |
| Tanaka, H | 1 |
| Ikeda, M | 1 |
| Kawazoe, S | 1 |
| Ohkawa, S | 1 |
| Sato, Y | 1 |
| Kaneko, S | 1 |
| Furuse, J | 1 |
| Takeuchi, M | 2 |
| Fang, X | 1 |
| Date, Y | 1 |
| Okusaka, T | 1 |
| Miyata, K | 1 |
| Ikawa, O | 1 |
| Izumi, H | 1 |
| Shimomura, K | 1 |
| Matsumura, H | 1 |
| Kakihara, N | 1 |
| Katoh, Y | 1 |
| Ohgaki, M | 1 |
| Iizuka, R | 1 |
| Fujii, K | 1 |
| Shimotsuma, M | 1 |
| Tkenaka, A | 1 |
| Meropol, NJ | 1 |
| Rustum, YM | 1 |
| Petrelli, NJ | 1 |
| Rodriguez-Bigas, M | 1 |
| Frank, C | 1 |
| Ho, DH | 1 |
| Kurowski, M | 1 |
| Creaven, PJ | 1 |
2 trials available for tegafur and Bilirubinemia
| Article | Year |
|---|---|
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hyperbilirubinemia; Leucovorin | 1996 |
1 other study available for tegafur and Bilirubinemia
| Article | Year |
|---|---|
[Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Dr | 2006 |